OneMedNet Bolsters Autoimmune Data Assets via ViuHealth Partnership

Event summary

  • OneMedNet has partnered with ViuHealth to expand its autoimmune clinical ontology and data scale.
  • The agreement integrates ViuHealth’s longitudinal autoimmune disease data into OneMedNet’s iRWD™ platform.
  • The partnership is intended to accelerate OneMedNet’s recurring revenue strategy, particularly within the $166+ billion autoimmune therapeutics market.
  • OneMedNet’s bookings grew 815% YoY and inbound demand increased 4.5X in the prior quarter (November 17, 2025).

The big picture

OneMedNet is strategically positioning itself as a critical infrastructure provider within the rapidly expanding real-world data market, specifically targeting high-value specialty areas like autoimmune diseases. This partnership underscores the shift towards subscription-based data models, moving away from transactional data sales and creating a more predictable revenue stream. The $166+ billion autoimmune therapeutics market represents a significant growth opportunity, but also a highly competitive landscape where data quality and insights are paramount.

What we're watching

Subscription Retention
The success of this partnership hinges on OneMedNet’s ability to retain ViuHealth’s data and convert it into long-term subscription revenue, rather than a one-time data purchase.
Data Quality
The value of OneMedNet’s offering is directly tied to the quality and longitudinal depth of the data acquired from ViuHealth; any degradation in data quality could undermine the platform’s appeal.
Foundry Dependency
OneMedNet’s reliance on Palantir Foundry introduces a potential dependency risk; changes in Palantir’s pricing or platform capabilities could significantly impact OneMedNet’s margins and operational flexibility.

Related topics

Partnership